Filtration surgery rates drop

Article

The introduction of anti-glaucoma medications has reduced the need for filtration surgery, according to study results published online ahead of print by Eye.

The introduction of anti-glaucoma medications has reduced the need for filtration surgery, according to study results published online ahead of print by Eye.

P.A. Keane of the Department of Ophthalmology at Waterford Regional Hospital, Ireland and colleagues conducted a 20-year retrospective review of patients undergoing glaucoma filtration surgery (n=760) at Waterford Regional Hospital between January 1986 and December 2005.

Over the review period, three new anti-glaucoma medicines became available. The number of filtration surgeries performed fell annually: from 1986–1995, the mean annual figure was 23.75 per surgeon; by the 1998–2005 period, this had fallen to 12.69 procedures per surgeon per year. The age of patients undergoing surgery did not decrease across the review period.

The team concluded that, as the decrease in filtration surgeries was not correlated to patient age, the introduction of topical anti-glaucoma medication was the most likely cause for the reduction, although it remains unclear whether this is an absolute reduction or merely a delay in the need for surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.